Lymphoma

Question 1

stage 1A hodgkins

Answer 1

2-4 cycles AVBD followed by IFRT; if low bulk <1/3 diameter or 10cm, then can give 2 cycles and 20Gy. if higher risk 4 Cycles and 30Gy

Question 2

less favorable stage 1A HL

Answer 2

3+ sites, elevated ESR>50, bulk, B-symptoms: give 4 cycles AVBD and 30Gy radiation

Question 3

brentuximab

Answer 3

anti-CD30, good for recurrent following auto

Question 4

IPS HL risk factors for advanced disease

Answer 4

age>45, male, stage IV(visceral/BM+), albumin15, ALC<600(8%)

Question 5

advanced HL high risk

Answer 5

consider escalated BEACOPP, but highly toxic

Question 6

second line HL regimens

Answer 6

ICE followed by autoSCT

Question 7

germinal cell type DLBCL

Answer 7

CD10+ BCL6+ MUM-1-

Question 8

poor prognosis DLBCL

Answer 8

+BCL2+

Question 9

low stage DLBCL

Answer 9

RCHOPx3–>RT unless risk of RT high, then can give RCHOP 4-6

Question 10

HLPHL nodular lymphocyte predominant HL

Answer 10

hystiocytic cells, popcorn like–> express CD20, CD79a, CD30-, good survival despite relapses, –> can treat first with RT, relapse with more RT v. ritux v ABVD

Question 11

CD20+CD5-CD10+CD23-

Answer 11

follicular lymphoma (CD10 positive–> most common)

Question 12

CD103, CD123, CD11c, TRAP

Answer 12

Hairy cell markers

Question 13

7q31 loss

Answer 13

splenic marginal zone

Question 14

villous projections on lymphocyte

Answer 14

HCV v. splenic MZL

Question 15

splenic MZL treatment

Answer 15

splenectomy; check for HCV as treatment of virus can result in remission

Question 16

CD20+ CD5-CD10-CD23-

Answer 16

MZL (pan negative BCL)

Question 17

t(11,18)

Answer 17

malt assocaited translocation- API2/MLT

Question 18

t(11,18) MALT lymphoma

Answer 18

resistant to Abx therapy

Question 19

t(14;18)

Answer 19

Bcl2 translocation

Question 20

maintenance/consolidation

Answer 20

rituximab q2mo x 2 year, or consolidation RIT, improves PFS without OS

Question 21

anaplastic large cell lymphoma

Answer 21

ALK translocation, CD30+ CD3+–> refractory treatment with brentuximab (can be CD3 negative)

Question 22

t(2;5)

Answer 22

ALK:NPM–>ALCL

Question 23

ALCL treatmetn

Answer 23

CHOP–>70% remission

Question 24

t(11;14) or CD23+

Answer 24

mantle cell lymphoma; treatment is contentious, but alternating chemoimmunotherapy is common

Question 25

MALT lymphoma H Pylori assocatied

Answer 25

treatment with antibiotic; localized can get radiotherapy;

Question 26

SLL with 11q-

Answer 26

particular benefit for including of an alkylating agent–> FCR or PCR